Mechanism of putative neo-antigen formation from N-propionyl-4-S- cysteaminylphenol, a tyrosinase substrate, in melanoma models

Shosuke Ito, Akira Nishigaki, Yasue Ishii-Osai, Makoto Ojika, Kazumasa Wakamatsu, Toshiharu Yamashita, Yasuaki Tamura, Akira Ito, Hiroyuki Honda, Eiichi Nakayama, Kowichi Jimbow

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Metastatic melanoma is resistant to conventional therapies. N-propionyl-4-S-cysteaminylphenol (NPrCAP), an N-protected sulfur-amine analog of tyrosine, is a good substrate for tyrosinase and is selectively incorporated into melanoma cells, causing cytotoxicity in vitro and in vivo. We have recently shown that intratumoral injections of NPrCAP suppress not only the growth of primary B16F1 melanoma tumors but also of secondary, re-challenged tumors. The participation of CD8 + T cells has been suggested for the NPrCAP-mediated anti-B16 melanoma immunity. In this study, the molecular mechanism of the NPrCAP cytotoxicity and immunogenicity was examined. The phenol NPrCAP was shown to be activated by mushroom tyrosinase to the ortho-quinone N-propionyl-4-S-cysteaminyl-1,2-benzoquinone (NPrCAQ), and the structure was confirmed by reducing it to the corresponding catechol. NPrCAQ reacted rapidly with biologically relevant sulfhydryl compounds such as cysteine, glutathione and bovine serum albumin. The NPrCAQ-thiol adduct formation was proven with a model thiol N-acetylcysteine by spectroscopic methods. The production and release of NPrCAQ-protein adducts was verified in B16F1 melanoma cells in vitro and in B16F1 melanoma-bearing mice in vivo through the detection of 5-S-cysteaminyl-3-S-cysteinylcatechol after acid hydrolysis of the protein fraction. These results suggest that the phenol NPrCAP, acting as a prohapten, can be activated in melanoma cells by tyrosinase to the quinone-hapten NPrCAQ, which binds to melanosomal proteins through their cysteine residues to form possible neo-antigens, thus triggering the immunological response. NPrCAP thus represents a potential new approach to immunotherapy against metastatic melanoma.

Original languageEnglish
Pages (from-to)646-653
Number of pages8
JournalBiochemical Pharmacology
Volume84
Issue number5
DOIs
Publication statusPublished - Sep 1 2012

Fingerprint

Monophenol Monooxygenase
Melanoma
Antigens
Substrates
Sulfhydryl Compounds
Cytotoxicity
Phenol
Cysteine
Tumors
Bearings (structural)
Experimental Melanomas
Proteins
T-cells
Haptens
Agaricales
Acetylcysteine
Bovine Serum Albumin
N-propionyl-4-S-cysteaminylphenol
Sulfur
Immunotherapy

All Science Journal Classification (ASJC) codes

  • Biochemistry
  • Pharmacology

Cite this

Mechanism of putative neo-antigen formation from N-propionyl-4-S- cysteaminylphenol, a tyrosinase substrate, in melanoma models. / Ito, Shosuke; Nishigaki, Akira; Ishii-Osai, Yasue; Ojika, Makoto; Wakamatsu, Kazumasa; Yamashita, Toshiharu; Tamura, Yasuaki; Ito, Akira; Honda, Hiroyuki; Nakayama, Eiichi; Jimbow, Kowichi.

In: Biochemical Pharmacology, Vol. 84, No. 5, 01.09.2012, p. 646-653.

Research output: Contribution to journalArticle

Ito, S, Nishigaki, A, Ishii-Osai, Y, Ojika, M, Wakamatsu, K, Yamashita, T, Tamura, Y, Ito, A, Honda, H, Nakayama, E & Jimbow, K 2012, 'Mechanism of putative neo-antigen formation from N-propionyl-4-S- cysteaminylphenol, a tyrosinase substrate, in melanoma models', Biochemical Pharmacology, vol. 84, no. 5, pp. 646-653. https://doi.org/10.1016/j.bcp.2012.06.015
Ito, Shosuke ; Nishigaki, Akira ; Ishii-Osai, Yasue ; Ojika, Makoto ; Wakamatsu, Kazumasa ; Yamashita, Toshiharu ; Tamura, Yasuaki ; Ito, Akira ; Honda, Hiroyuki ; Nakayama, Eiichi ; Jimbow, Kowichi. / Mechanism of putative neo-antigen formation from N-propionyl-4-S- cysteaminylphenol, a tyrosinase substrate, in melanoma models. In: Biochemical Pharmacology. 2012 ; Vol. 84, No. 5. pp. 646-653.
@article{5fe5e868607f455ba4a81edb29ee53fd,
title = "Mechanism of putative neo-antigen formation from N-propionyl-4-S- cysteaminylphenol, a tyrosinase substrate, in melanoma models",
abstract = "Metastatic melanoma is resistant to conventional therapies. N-propionyl-4-S-cysteaminylphenol (NPrCAP), an N-protected sulfur-amine analog of tyrosine, is a good substrate for tyrosinase and is selectively incorporated into melanoma cells, causing cytotoxicity in vitro and in vivo. We have recently shown that intratumoral injections of NPrCAP suppress not only the growth of primary B16F1 melanoma tumors but also of secondary, re-challenged tumors. The participation of CD8 + T cells has been suggested for the NPrCAP-mediated anti-B16 melanoma immunity. In this study, the molecular mechanism of the NPrCAP cytotoxicity and immunogenicity was examined. The phenol NPrCAP was shown to be activated by mushroom tyrosinase to the ortho-quinone N-propionyl-4-S-cysteaminyl-1,2-benzoquinone (NPrCAQ), and the structure was confirmed by reducing it to the corresponding catechol. NPrCAQ reacted rapidly with biologically relevant sulfhydryl compounds such as cysteine, glutathione and bovine serum albumin. The NPrCAQ-thiol adduct formation was proven with a model thiol N-acetylcysteine by spectroscopic methods. The production and release of NPrCAQ-protein adducts was verified in B16F1 melanoma cells in vitro and in B16F1 melanoma-bearing mice in vivo through the detection of 5-S-cysteaminyl-3-S-cysteinylcatechol after acid hydrolysis of the protein fraction. These results suggest that the phenol NPrCAP, acting as a prohapten, can be activated in melanoma cells by tyrosinase to the quinone-hapten NPrCAQ, which binds to melanosomal proteins through their cysteine residues to form possible neo-antigens, thus triggering the immunological response. NPrCAP thus represents a potential new approach to immunotherapy against metastatic melanoma.",
author = "Shosuke Ito and Akira Nishigaki and Yasue Ishii-Osai and Makoto Ojika and Kazumasa Wakamatsu and Toshiharu Yamashita and Yasuaki Tamura and Akira Ito and Hiroyuki Honda and Eiichi Nakayama and Kowichi Jimbow",
year = "2012",
month = "9",
day = "1",
doi = "10.1016/j.bcp.2012.06.015",
language = "English",
volume = "84",
pages = "646--653",
journal = "Biochemical Pharmacology",
issn = "0006-2952",
publisher = "Elsevier Inc.",
number = "5",

}

TY - JOUR

T1 - Mechanism of putative neo-antigen formation from N-propionyl-4-S- cysteaminylphenol, a tyrosinase substrate, in melanoma models

AU - Ito, Shosuke

AU - Nishigaki, Akira

AU - Ishii-Osai, Yasue

AU - Ojika, Makoto

AU - Wakamatsu, Kazumasa

AU - Yamashita, Toshiharu

AU - Tamura, Yasuaki

AU - Ito, Akira

AU - Honda, Hiroyuki

AU - Nakayama, Eiichi

AU - Jimbow, Kowichi

PY - 2012/9/1

Y1 - 2012/9/1

N2 - Metastatic melanoma is resistant to conventional therapies. N-propionyl-4-S-cysteaminylphenol (NPrCAP), an N-protected sulfur-amine analog of tyrosine, is a good substrate for tyrosinase and is selectively incorporated into melanoma cells, causing cytotoxicity in vitro and in vivo. We have recently shown that intratumoral injections of NPrCAP suppress not only the growth of primary B16F1 melanoma tumors but also of secondary, re-challenged tumors. The participation of CD8 + T cells has been suggested for the NPrCAP-mediated anti-B16 melanoma immunity. In this study, the molecular mechanism of the NPrCAP cytotoxicity and immunogenicity was examined. The phenol NPrCAP was shown to be activated by mushroom tyrosinase to the ortho-quinone N-propionyl-4-S-cysteaminyl-1,2-benzoquinone (NPrCAQ), and the structure was confirmed by reducing it to the corresponding catechol. NPrCAQ reacted rapidly with biologically relevant sulfhydryl compounds such as cysteine, glutathione and bovine serum albumin. The NPrCAQ-thiol adduct formation was proven with a model thiol N-acetylcysteine by spectroscopic methods. The production and release of NPrCAQ-protein adducts was verified in B16F1 melanoma cells in vitro and in B16F1 melanoma-bearing mice in vivo through the detection of 5-S-cysteaminyl-3-S-cysteinylcatechol after acid hydrolysis of the protein fraction. These results suggest that the phenol NPrCAP, acting as a prohapten, can be activated in melanoma cells by tyrosinase to the quinone-hapten NPrCAQ, which binds to melanosomal proteins through their cysteine residues to form possible neo-antigens, thus triggering the immunological response. NPrCAP thus represents a potential new approach to immunotherapy against metastatic melanoma.

AB - Metastatic melanoma is resistant to conventional therapies. N-propionyl-4-S-cysteaminylphenol (NPrCAP), an N-protected sulfur-amine analog of tyrosine, is a good substrate for tyrosinase and is selectively incorporated into melanoma cells, causing cytotoxicity in vitro and in vivo. We have recently shown that intratumoral injections of NPrCAP suppress not only the growth of primary B16F1 melanoma tumors but also of secondary, re-challenged tumors. The participation of CD8 + T cells has been suggested for the NPrCAP-mediated anti-B16 melanoma immunity. In this study, the molecular mechanism of the NPrCAP cytotoxicity and immunogenicity was examined. The phenol NPrCAP was shown to be activated by mushroom tyrosinase to the ortho-quinone N-propionyl-4-S-cysteaminyl-1,2-benzoquinone (NPrCAQ), and the structure was confirmed by reducing it to the corresponding catechol. NPrCAQ reacted rapidly with biologically relevant sulfhydryl compounds such as cysteine, glutathione and bovine serum albumin. The NPrCAQ-thiol adduct formation was proven with a model thiol N-acetylcysteine by spectroscopic methods. The production and release of NPrCAQ-protein adducts was verified in B16F1 melanoma cells in vitro and in B16F1 melanoma-bearing mice in vivo through the detection of 5-S-cysteaminyl-3-S-cysteinylcatechol after acid hydrolysis of the protein fraction. These results suggest that the phenol NPrCAP, acting as a prohapten, can be activated in melanoma cells by tyrosinase to the quinone-hapten NPrCAQ, which binds to melanosomal proteins through their cysteine residues to form possible neo-antigens, thus triggering the immunological response. NPrCAP thus represents a potential new approach to immunotherapy against metastatic melanoma.

UR - http://www.scopus.com/inward/record.url?scp=84864397994&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84864397994&partnerID=8YFLogxK

U2 - 10.1016/j.bcp.2012.06.015

DO - 10.1016/j.bcp.2012.06.015

M3 - Article

C2 - 22728921

AN - SCOPUS:84864397994

VL - 84

SP - 646

EP - 653

JO - Biochemical Pharmacology

JF - Biochemical Pharmacology

SN - 0006-2952

IS - 5

ER -